{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:11:43Z","timestamp":1792663903518,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaad.2023.04.061","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T01:54:52Z","timestamp":1683683692000},"page":"936-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Jerry","family":"Bagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Yen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.04.061_bib1","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jaad.2023.04.061_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib3","first-page":"258","article-title":"Disease burden and treatment adherence in psoriasis patients","volume":"92","author":"Feldman","year":"2013","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2023.04.061_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"17","author":"Lebwohl","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib6","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2147\/PPA.S117006","article-title":"Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature","volume":"10","author":"Belinch\u00f3n","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaad.2023.04.061_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13555-019-00334-1","article-title":"Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey","volume":"9","author":"Gorelick","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.061_bib8","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s13555-021-00620-x","article-title":"Characterizing outcomes and unmet needs among patients in the United States with mild-to-moderate plaque psoriasis using prescription topicals","volume":"11","author":"Gupta","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.061_bib9","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s12325-022-02124-2","article-title":"Treatment goals for psoriasis as measured by Patient Benefit Index: results of a National Psoriasis Foundation survey","volume":"39","author":"Armstrong","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaad.2023.04.061_bib10","first-page":"4","article-title":"Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization","volume":"18","author":"Armstrong","year":"2018","journal-title":"BMC\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CEOR.S251775","article-title":"Switch rates and total cost of care associated with apremilast and biologic therapies in biologic-naive patients with plaque psoriasis","volume":"12","author":"Kaplan","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jaad.2023.04.061_bib12","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jaad.2019.01.039","article-title":"Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States","volume":"80","author":"Feldman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2023.04.061_bib14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.04.061_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjd.14788","article-title":"A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis","volume":"176","author":"Ali","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD\u2013NPF guidelines of care for the management and treatment of\u00a0psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaad.2023.04.061_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1524-4733.2008.00323.x","article-title":"Development and validation of the \u201cTreatment Satisfaction with Medicines Questionnaire\u201d (SATMED-Q)","volume":"11","author":"Ruiz","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jaad.2023.04.061_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000501582","article-title":"Examination of treatment satisfaction instruments in psoriasis: 2017 results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM)","volume":"237","author":"Kornmehl","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2023.04.061_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamadermatol.2020.5844","article-title":"Association of patient mental health status with the level of agreement between patient and physician ratings of psoriasis severity","volume":"157","author":"Carr","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/jdv.14937","article-title":"Patient\u2013dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey","volume":"32","author":"Griffiths","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.04.061_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2475530319854781","article-title":"Correlation of physician-assessed Psoriasis Area and Severity Index scores with patient-reported psoriasis symptoms and signs diary scores among patients with moderate-to-severe psoriasis: results from VOYAGE 1 and VOYAGE 2 studies","volume":"4","author":"Gordon","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.jaad.2023.04.061_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/09546634.2016.1254331","article-title":"Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review","volume":"28","author":"Svendsen","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2023.04.061_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2005.01329.x","article-title":"How patients experience psoriasis: results from a European survey","volume":"19","author":"Fouere","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.04.061_bib27","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2023.04.061_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.04.061_bib30","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.04.061_bib31","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Strober B, Lebwohl M, et\u00a0al. Tapinarof cream 1% once daily for plaque psoriasis: patient-reported outcomes from two pivotal phase 3 trials. International Federation of Psoriasis Association (virtual), June 30-July 3, 2021.","DOI":"10.1016\/j.jaad.2021.06.310"},{"key":"10.1016\/j.jaad.2023.04.061_bib32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial","volume":"87","author":"Strober","year":"2022","journal-title":"J Am Acad\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib33","article-title":"Tapinarof cream 1% once daily for plaque psoriasis: Dermatology Life Quality Index and local tolerability scores from a long-term extension trial","volume":"25-29","author":"Armstrong","year":"2022","journal-title":"American Academy of Dermatology; March"},{"key":"10.1016\/j.jaad.2023.04.061_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.04.061_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2340\/00015555-2833","article-title":"Correlation between dermatology life quality index and Psoriasis Area and Severity Index in patients with psoriasis treated with ustekinumab","volume":"98","author":"Hesselvig","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.04.061_bib36","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s13555-021-00564-2","article-title":"Correlation between change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab","volume":"11","author":"Houghton","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.04.061_bib37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-020-00428-1","article-title":"Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in\u00a0real life (PSO-BIO-REAL)","volume":"10","author":"Lacour","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.061_bib38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13555-021-00649-y","article-title":"Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes\u00a0in a phase 2 trial","volume":"12","author":"Tha\u00e7i","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.061_bib39","doi-asserted-by":"crossref","unstructured":"Gold LS, Tallman A, Brown PM, Lebwohl M. Tapinarof cream 1% once daily for plaque psoriasis: improvements in quality of life and clinical efficacy in two pivotal phase 3 trials. European Academy of Dermatology and Venereology Congress; September 7-10, 2022; Milan, Italy.","DOI":"10.25251\/skin.7.supp.123"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223007715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223007715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:03Z","timestamp":1759274883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223007715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0190962223007715"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.061","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}